,,,,,no need for FUD around IP or future financing. This company possibly has enuff self-interested insiders to make a deal/s going forward.

The share price however is a direct result of DM not being able to sell the advanced state and credibility of this science. All shareholders suffer because of this inability, including DM and the insiders. I am not sure but that these insiders do enjoy a low share price which favours PP negotiating ability with the company. Why then would we be sitting on progressive and positive information/data,,,it only benefits those mentioned above.

As CEO, DM has to bare the full responsibility of where we presently sit. The market does not believe we are block buster science, and that is where DM has and continues to knowingly fail in his marketing. We certainly cant say he has a strategy cuz there seems to be a void of such when shareholders are forwarding info to parties that are unaware of our epigenetic research!

We all have been holding dead money in this so called "very exciting science",,the tiring expression that makes me cringe when I hear it come from RVX.....ugghhhhh,,,,,88 cents as I type,,,,,jmo,,